The phases of clinical trials are structured stages researchers use to evaluate the safety, effectiveness, dosage, and long-term impact of investigational drugs, biologics, and medical devices. Clinical trials typically progress through four phases — Phase I, Phase II, Phase III, and Phase IV — with each phase serving a distinct role in protecting participants and generating reliable scientific evidence.
Clinical trials are studies involving human volunteers to research ways to prevent, detect, and treat various medical conditions. The goal is to identify safer, more effective methods of treating illnesses using new drugs or new combinations of existing drugs.
This article explores how the clinical research phases protect study volunteers from harm and ensure new drugs and therapies are developed effectively.
The Importance of Clinical Research in Medical Advancements
Researchers use clinical trials to test the safety and efficacy of a drug or other medical treatment. Most modern medicines were developed from clinical trials, and clinical trials remain essential for drug development.
Without clinical studies, our global understanding of medicine would likely stagnate, and novel treatments would cease to emerge. Currently incurable diseases would remain so, without any improvements made to existing drugs and therapies.
Therefore, clinical research is a fundamental aspect of medical advancement. It is the best way for scientists to fully observe and analyze how drugs interact with the human body, and their efficacy as treatments for disease. Clinical trials also allow researchers to further their understanding of specific diseases, which may help identify new potential angles for treatment.
The Four Phases of Clinical Trials
Clinical trials studying drugs or treatments take place in four main phases. Each phase includes specific elements to ensure participant safety, experiment accuracy, and reliable results.
Phase I: Safety Evaluation
The objective of a Phase I clinical trial is to assess a potential new treatment’s safety, side effects, and dose. Some Phase I trials are also first-in-human (FIH) studies, meaning the treatment has not previously been tested in people.
The aim of a Phase I trial is to determine:
- Whether the treatment is safe to give to humans
- Potential treatment side effects
- In drug trials: how much of the drug is safe to give, and what happens to the drug within the body
Phase I clinical research is usually performed on a small number of healthy participants. These trials typically begin with the administration of a very low dose of the investigational treatment. If the treatment does not produce unacceptable side effects, researchers may increase the dosage.
During the study, researchers observe and record any side effects related to the investigational treatment, along with their severity and dose-dependence. Researchers also look for indications of the treatment positively affecting the target illness.
Phase II: Efficacy and Side Effects
Phase II clinical trials evaluate whether an investigational treatment is effective for patients with the target condition while continuing to monitor safety.
Once an experimental treatment is determined successful in Phase I, it can enter the second phase of clinical testing. The goal of Phase II clinical trials is to evaluate whether an investigational treatment is effective for patients with the target condition while continuing to monitor safety.
These studies typically involve a larger group of participants than Phase I (usually 100 – 300 patients), all of whom have the condition the study therapy aims to treat.
Phase II trials usually determine:
- Which doses of the treatment are safe to give to humans
- What side effects are associated with the treatment (and how to manage them)
- Whether or not the treatment is effective
- The safety and effectiveness of the new treatment compared to existing treatments
Participants in Phase II clinical trials are usually given the highest “safe” dose of the treatment identified in Phase I. They are then monitored for side effects and signs of effective treatment.
In some Phase II trials, participants are divided into two or more groups. One group may receive the standard treatment for their condition, while others receive the treatment under study. Sometimes, different groups are given different doses of the same therapies.
Comparing the treatment outcomes of these different groups allows researchers to assess the effectiveness of new vs. existing therapies. It also furthers their understanding of the experimental treatment’s dose-dependent outcomes (i.e., the effect on illnesses and side effects each dose may produce).
Phase III: Confirming Safety and Effectiveness
Phase III clinical trials involve larger patient populations and compare investigational therapies against standard treatments or placebos.
Phase III trials are performed on a larger population sample than Phase I or Phase II, usually involving anywhere from 300 – 3,000 participants. These patients are often divided into random groups to receive different doses and combinations of treatments. This allows researchers to investigate:
- How effective the treatment is compared to standard treatments
- How effective the treatment is at different doses
- The type, frequency, and severity of side effects associated with new vs. existing treatments
- How the treatment affects a patient’s quality of life compared to standard treatments
Drugs performing well in Phase III trials are often put forward for government regulatory approval. Approval confirms the experimental drug or therapy meets the government’s standards for safety and efficacy, and can be used to treat patients outside of clinical trials.
Phase IV Clinical Trials: Post-Market Safety Monitoring
Phase IV clinical trials, also known as post-marketing or therapeutic use studies, are performed after regulatory approval and monitor long-term safety, effectiveness, and rare adverse events in broader patient populations.
Post-market monitoring is important because side effects affecting very few people (for example, 1 in 1000 people) may not always emerge during a Phase III trial. However, such effects can appear more frequently once a treatment is approved for use among the general population.
It is crucial for researchers to engage in ongoing study of the drug so they can identify and manage any serious side effects in participants.
During a Phase IV trial, researchers will observe:
- The frequency and severity of rare side effects in the general population
- The safety of the treatment for those who experience rare side effects
- The long-term risks and benefits associated with the treatment
- The efficacy of the treatment across a larger population sample size
- The risks and benefits of the treatment at different doses
- The risks and benefits of the treatment in combination with other treatments
Comparison of the Phases of Clinical Trials
| Phase | Primary Goal | Participants | Primary Focus |
| Phase I | Evaluate safety and dosage | 20–100 | Safety and side effects |
| Phase II | Evaluate effectiveness | 100–300 | Efficacy and dosing |
| Phase III | Compare to standard treatment | 300–3,000 | Safety and efficacy confirmation |
| Phase IV | Monitor post-market safety | Large populations | Long-term safety monitoring |
How the Phases of Clinical Trials Support Medical Innovation and Patient Care
The phases of clinical trials play a critical role in advancing medical research and improving patient outcomes. Each phase of clinical research helps researchers gather important information about an investigational treatment’s safety, effectiveness, dosage, and long-term risks before it becomes widely available to patients. This structured process helps protect research participants while supporting the development of new therapies, vaccines, and medical devices.
Clinical trials have contributed to many of the medical advances now considered standard of care, including treatments for cancer, cardiovascular disease, neurological disorders, and rare diseases.
Through each phase of a clinical trial, researchers can better understand how treatments interact with the human body, how side effects should be managed, and which patient populations may benefit most from a therapy.
The different phases of clinical trials also support the development of disease prevention and disease management strategies. For example, Phase III and Phase IV studies often provide valuable data about long-term treatment outcomes, quality of life improvements, and real-world safety considerations. Clinical research has also played a major role in the development of vaccines and preventative therapies for infectious diseases such as Ebola and Zika virus.
By progressing through Phase I, Phase II, Phase III, and Phase IV clinical trials, investigational therapies undergo a rigorous evaluation process designed to support both scientific advancement and participant safety. The knowledge gained throughout the clinical trial process helps researchers, healthcare providers, sponsors, and regulators continue developing safer and more effective treatments for patients worldwide.
Key Takeaways About the Phases of Clinical Trials
- Clinical trials typically progress through four phases: Phase I, II, III, and IV.
- Each clinical trial phase evaluates different aspects of a treatment’s safety and effectiveness.
- Phase I focuses primarily on safety and dosage.
- Phase II and Phase III evaluate efficacy, side effects, and comparisons to standard therapies.
- Phase IV clinical trials monitor long-term safety and effectiveness after regulatory approval.
